TFF1-mediated suppression of the TCA cycle promotes bone metastasis in triple-negative breast cancer.
TFF1 suppresses the TCA cycle in TNBC, promoting bone metastasis, but findings are based on mouse models and need human validation.
Where it sits
this study against the rest of the abaloparatide (tymlos) corpusSummary and findings
The study investigates the role of TFF1 in the suppression of the TCA cycle in triple-negative breast cancer (TNBC) and its impact on bone metastasis. Using a bone-tropic TNBC subline developed in mice, the study identifies TFF1 as a key regulator of TCA cycle gene expression. Deletion of TFF1 was shown to enhance mitochondrial function and reduce metastatic burden in vivo.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by limited treatment options and poor prognosis. While TNBC exhibits a lower incidence of bone metastasis compared to luminal subtypes, its occurrence is associated with substantial morbidity and mortality. The metabolic mechanisms enabling TNBC cells to colonize bone remain largely undefined. In this study, a bone-tropic TNBC subline (MDA-MB-231/BM) was developed through iterative intracardiac inoculation in mice, followed by transcriptomic profiling to identify genes with altered expression. A CRISPR/Cas9 knockout library screen in MDA-MB-231 cells further revealed critical regulators of bone metastasis. Notably, dual-omics analysis demonstrated a consistent downregulation of key enzymes in the tricarboxylic acid (TCA) cycle within bone-metastatic TNBC cells. Functional experiments showed that PDHA1 knockout impaired cell migration, invasion, and mitochondrial respiration, underscoring the TCA cycle's essential role in metastasis. Among the identified regulators, TFF1 emerged as a potent suppressor of TCA cycle gene expression. Deletion of TFF1 enhanced mitochondrial function, reduced metastatic burden in vivo, and extended survival in mouse models. Supporting clinical relevance, TCGA data showed significantly higher TFF1 expression in luminal breast cancer compared to TNBC, aligning with the greater propensity for bone metastasis in luminal subtypes. These findings reveal that TFF1-mediated suppression of the TCA cycle contributes to the metabolic adaptation of TNBC cells for bone colonization, offering a potential therapeutic vulnerability and advocating for subtype-specific metabolic interventions.
Background
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited treatment options and a poor prognosis. Although TNBC has a lower incidence of bone metastasis compared to luminal subtypes, its occurrence is associated with significant morbidity and mortality. Understanding the metabolic mechanisms that enable TNBC cells to colonize bone is crucial for developing targeted therapies.
Methods
The study developed a bone-tropic TNBC subline (MDA-MB-231/BM) through iterative intracardiac inoculation in mice. Transcriptomic profiling was conducted to identify genes with altered expression. A CRISPR/Cas9 knockout library screen was used in MDA-MB-231 cells to reveal critical regulators of bone metastasis. Dual-omics analysis was performed to assess TCA cycle enzyme expression, and functional experiments evaluated the effects of PDHA1 knockout on cell behavior.
Results
The primary finding was the downregulation of key enzymes in the TCA cycle within bone-metastatic TNBC cells. Functional experiments demonstrated that PDHA1 knockout impaired cell migration, invasion, and mitochondrial respiration. TFF1 was identified as a suppressor of TCA cycle gene expression, and its deletion enhanced mitochondrial function, reduced metastatic burden, and extended survival in mouse models.
Interpretation
The study suggests that TFF1-mediated suppression of the TCA cycle is a metabolic adaptation that facilitates TNBC bone metastasis. While the findings offer a potential therapeutic target, the clinical significance remains uncertain due to the reliance on animal models. The study highlights the need for further research to validate these findings in human clinical settings.
Key findings
- Significant downregulation of TCA cycle enzymes in bone-metastatic TNBC cells.
- PDHA1 knockout impaired cell migration, invasion, and mitochondrial respiration.
- Deletion of TFF1 reduced metastatic burden and extended survival in mouse models.
- Higher TFF1 expression in luminal breast cancer compared to TNBC in TCGA data.
Limitations
- Mouse model study, not directly translatable to humans.
- Focus on cellular and animal experiments, lacking human data.
- Potential confounding factors in CRISPR/Cas9 knockout library screen.